Menu Search
Equities

New Nordic Healthbrands AB

N9X:DEU

New Nordic Healthbrands AB

Actions
  • Price (--)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
--
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

New Nordic Healthbrands AB (New Nordic) is a Sweden-based food supplement and naturopathy company. The Company develops and sells dietary supplements, herbal remedies and related personal care products. New Nordic offers products in such segments as Diet, which includes brand names Apple Cider, BioFirm and Chili Burn, among others; Vitality, which includes brands Blue Berry, Frutin, Active Liver and dida, among others, and Beauty, which includes product lines Hair Volume, Nail Strong and Skin Care, among others. New Nordic's products are available in more than 30 countries, with focus on the Nordic region and the United States.

  • Revenue in SEK (TTM)548.77m
  • Net income in SEK-11.56m
  • Incorporated2006
  • Employees71.00
  • Location
    New Nordic Healthbrands ABThe Point, Hyllie Boulevard 34MALMO 215 32SwedenSWE
  • Phone+46 446236414
  • Fax+46 40239522
  • Websitehttps://newnordic.se/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.